ARA-290 (Cibinetide) Protocol — Complete Dosing & Administration Guide

Dosing

How muchdo I take?

Subcutaneous: A small injection into the fatty layer just under the skin — the same way insulin is given.

Bioavailability High — most of the dose reaches your bloodstream, just more gradually than an IV.

Starting Dose

1 mg

Frequency

Once daily

Duration

28 days

Lowest dose tested in the phase 2 sarcoidosis nerve study. A good starting point while watching how the body responds [1].

Standard Dose

4 mg

The 4 mg dose gave the strongest nerve-fiber regrowth and pain relief in the trial — better than the higher 8 mg dose [1][2].

Advanced Dose

8 mg

Highest daily dose studied in the sarcoidosis trial. It was safe but did not beat 4 mg for nerve outcomes [1].

Timing

Best time to take

Administer ARA-290 (Cibinetide) at the same time each day (or on the same day each week for weekly injections). Many users prefer morning or evening administration. Pick a time you'll remember consistently.

With food?

ARA-290 (Cibinetide) injections can be given regardless of meal timing. However, if GI effects occur, administering on an empty stomach or with a light meal may help reduce discomfort.

If stacking

ARA-290 (Cibinetide) should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.

Adjusting Your Dose

Increase if

+You've tolerated the current dose for the recommended period without significant side effects

+Therapeutic goals haven't been met at the current dose level

+Your healthcare provider recommends dose escalation based on your response

+Lab work or clinical assessments support a higher dose

Decrease if

-Side effects are bothersome or impacting daily life despite management strategies

-You experience any signs of an adverse reaction

-Lab results indicate the need for dose reduction

-Your healthcare provider recommends a lower dose based on your response

Signs of right dose

✓Therapeutic goals being met with minimal side effects

✓Stable and consistent response to treatment

✓Lab values or clinical markers trending in the right direction

✓Good tolerance with manageable or absent side effects

Dosing Calculator

Calculate Your Exact Dose

Step 1: Peptide Weight

Find the weight printed on your peptide vial label

Look here!

The peptide weight is printed on the label

The weight is on the label

Select Weight

Look for a number followed by 'mg' on the vial label (e.g., 5mg, 10mg)

Administration

How do Iuse it?

Reconstitution

What you need

•ARA-290 (Cibinetide) vial (lyophilized powder or solution)

•Bacteriostatic water or sterile sodium chloride for reconstitution

•Alcohol swabs for cleaning vial tops and injection sites

•Appropriately sized syringes with fine-gauge needles (27-30 gauge)

•Sharps disposal container

Example

Add the recommended volume of bacteriostatic water to the ARA-290 (Cibinetide) vial. Gently swirl (do not shake) until the powder is fully dissolved. The resulting solution should be clear. Calculate your individual dose based on the concentration and your prescribed amount.

Your dose of ARA-290 (Cibinetide) is determined by your healthcare provider. Using an insulin syringe marked in units, draw up the exact amount prescribed. For example, if the reconstituted concentration is 1mg/mL and your dose is 0.5mg, draw up 0.5mL (50 units on an insulin syringe). Always double-check calculations before injection.

Injection

Route

Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training

Best sites

•Abdomen (stomach area)—at least 2 inches from the belly button, most popular choice for self-injection

•Front of thighs—middle to upper portion of the outer leg

•Back of upper arm—outer area (may need assistance from another person)

Technique

1.Wash your hands thoroughly with soap and water before handling supplies

2.Clean the injection site with an alcohol swab and let it air dry completely

3.Pinch a fold of skin at the chosen injection site

4.Insert the needle at a 45-90 degree angle (depending on needle length and body composition)

5.Inject the medication slowly and steadily over 5-10 seconds

6.Release the skin fold and remove the needle, applying gentle pressure with a clean swab

7.Rotate injection sites to prevent tissue irritation or lipodystrophy

8.Dispose of the needle safely in a sharps container—never recap or reuse needles

Storage

Before reconstitution

Store ARA-290 (Cibinetide) in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.

After reconstitution

Once reconstituted, ARA-290 (Cibinetide) should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.

Signs of degradation

Solution appears cloudy, discolored, or contains visible particles (should be clear)

Product has been exposed to temperatures outside the recommended storage range

Product has been frozen (unless specifically designed for freeze-thaw stability)

Expiration date has passed or reconstituted solution has exceeded its use-by date

Unusual odor, color change, or visible contamination

Sample Daily Schedule

As prescribed (once daily)

As prescribed by your healthcare provider injection

Site: Subcutaneous injection—rotate sites if applicable

Maintain a consistent schedule for optimal results with ARA-290 (Cibinetide). Set reminders if needed. If you miss a dose, follow your healthcare provider's instructions—do not double up on doses to compensate.

Safety

Is itsafe?

Safety Profile

ARA-290 is a synthetic innate repair receptor agonist that has completed Phase 2 clinical trials for small fiber neuropathy and is under active development. Animal toxicology studies show a good safety margin with no organ damage or cytotoxicity at doses far exceeding therapeutic levels. Early clinical data from Phase 2 trials demonstrate tolerability with mild injection site reactions and transient headache as primary concerns. However, immunogenicity remains a potential risk with repeated dosing of synthetic peptides, requiring anti-drug antibody monitoring. Long-term safety data beyond 12 weeks does not yet exist.

Evidence comes from preclinical toxicology studies, Phase 1 dose-escalation and safety data, and Phase 2 efficacy trials in small fiber neuropathy patients. The phase 2 trial enrolled 127 patients with a primary endpoint of safety and tolerability. No serious adverse events directly attributable to ARA-290 were reported in early studies. Data suggests good safety at doses up to 1 mg subcutaneously twice weekly, but longer-term outcomes and immunogenicity assessments continue.

Common Side Effects

Experienced by some users

Injection Site Reactions

Redness, mild swelling, or bruising at injection site lasting a few hours to a day

Management: Rotate injection sites, apply ice pack after injection, massage gently to improve absorption

Headache

Mild to moderate headache typically in first few hours after injection

Management: Stay hydrated, rest in a quiet space, over-the-counter pain reliever if needed

Dizziness

Brief dizziness or lightheadedness, especially when standing up quickly

Management: Rise slowly from sitting or lying, avoid sudden movements, inform your doctor if persistent

Less Common

•Elevated Blood Pressure

•Fatigue

These typically resolve with continued use or dose adjustment.

Stop and Seek Help If

×Severe or worsening side effects that don't improve with dose adjustment or supportive care

×Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing

×Your healthcare provider recommends discontinuation based on your clinical response

×Development of any new medical condition that may be contraindicated with ARA-290 (Cibinetide)

×Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)

×Abnormal lab results or clinical markers that suggest adverse effects

ARA-290 (Cibinetide) should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.

Interactions

With other peptides

✓Enhances antioxidant protection and reduces inflammation to complement nerve regeneration

✓Fat-soluble form of B1 vitamin that supports nerve function alongside ARA-290's regenerative effects

✓Essential for nerve health and myelin formation, works synergistically with nerve repair

With medications

!Erythropoietin (EPO) - Both activate similar pathways; combining could cause excessive red blood cell production

!Uncontrolled antihypertensive medications - May cause dangerous blood pressure fluctuations

!Anticoagulants at high doses - May increase thrombosis risk

With supplements

✓Multivitamins - Generally safe to take alongside ARA-290 (Cibinetide). Space doses apart if taking oral formulations to ensure optimal absorption.

✓Electrolyte supplements - Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.

Want the Full Picture?

View the complete ARA-290 (Cibinetide) research profile including mechanism of action, clinical studies, effectiveness timeline, and FAQ.